Skip to content
Agentic OS
Menu

Intelligence / Logistics & supply chain market map / Cold-chain infrastructure and monitoring equipment / Temperature-monitoring, telemetry and control systems / Pharma & biologics temperature-controlled shipping compliance monitoring

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Pharma & biologics temperature-controlled shipping compliance monitoring

Data loggers, calibrated temperature sensors, and cloud-connected monitoring systems bought by pharmaceutical manufacturers, CDMOs and specialty couriers to produce documented, audit-ready evidence that biologics, vaccines and cell therapies stayed within 2-8C from plant to patient, as required by FDA 21 CFR Part 211, EU GMP Annex 15 and WHO GDP guidelines.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
85 /100
for B2B sellers
Evidence
not sized
5 sources · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Pharmaceutical manufacturers, CDMOs and clinical supply chain managers
Buying centre
Quality Assurance / Qualified Person (decision), with Supply Chain and IT (influencers) and Procurement (commercial terms)
Buying triggers
  • New biologic or vaccine launch requiring validated cold-chain lanes
  • Regulatory inspection or audit finding on temperature excursion records
  • Loss of a temperature-controlled shipment or excursion event
  • EU GMP Annex 15 / WHO GDP qualification of a new site or lane
Pains
  • Cannot produce per-shipment temperature evidence on demand
  • Excursions discovered only at delivery, after product value is lost
  • Manual logger downloads and reconciliation consume QA hours
  • Unvalidated lanes cause batch rejection and regulatory exposure
Scores (1–5)
Pain intensity5
Purchasing power4
Reachability3
Growth5

How this was sized

Not sized yet

No source splits cold chain monitoring by end-use vertical, so no defensible size can be attributed to pharma alone. Directional support only: the monitoring market is USD 8.40bn (2025) rising to USD 9.50bn (2026) and USD 19.54bn (2032) at 12.8% CAGR [2]; a separate estimate puts 2025 at USD 9.07bn with 9.0% CAGR to 2035 [5]; regulatory drivers for pharma are explicitly cited in [5]. Sizing this niche requires a pharma share of monitoring spend that no source provides.

Alongside it in Temperature-monitoring, telemetry and control systems

// Sell into Pharma & biologics temperature-controlled shipping compliance monitoring

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.